Bromocriptine Mesylate and Tacrolimus Injection
Determining the interaction of Bromocriptine Mesylate and Tacrolimus Injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Bromocriptine may increase the blood levels of tacrolimus. In some cases, this can increase the risk of serious side effects such as kidney problems, diabetes, nervous system disorders, hyperkalemia (high potassium levels in the blood), high blood pressure, irregular heart rhythm, heart failure, infections, and various types of malignancies including lymphoma and skin cancer. You may need a dose adjustment if you have been taking tacrolimus and are starting treatment with bromocriptine. Contact your doctor if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Also seek medical attention if you experience frequent urination, increased hunger or thirst, loss of appetite, confusion, tremor, numbness or tingling, seizures, vision changes, sudden dizziness, lightheadedness, fainting, shortness of breath, heart palpitations, and chest pain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with drugs that are inhibitors of CYP450 3A4 may increase the blood concentrations of the macrolide immunosuppressants sirolimus and tacrolimus, both of which are metabolized by the isoenzyme.
MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of macrolide immunosuppressant therapy should be considered, including adverse effects such as fever, infection, diarrhea, hypokalemia, anemia, thrombocytopenia, leukopenia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
- "Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.
- "Product Information. Rapamune (sirolimus)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
- Christians U, Schmidt G, Bader A, et al "Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes." Br J Clin Pharmacol 41 (1996): 187-90
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: bromocriptine
Brand name: Parlodel, Cycloset
Synonyms: Bromocriptine
Generic Name: tacrolimus
Brand name: Astagraf XL, Envarsus XR, Prograf, Hecoria
Synonyms: Tacrolimus (oral and injection), Tacrolimus (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Bromocriptine Mesylate-Tacrolimus Intravenous
- Bromocriptine Mesylate-Tacrolimus oral and injection
- Bromocriptine Mesylate-Tacrolimus Oral, Intravenous
- Bromocriptine Mesylate-Tactinal
- Bromocriptine Mesylate-Tadalafil
- Bromocriptine Mesylate-Tadalafil Tablets (Cialis)
- Tacrolimus Injection-Brompheniramine
- Tacrolimus Injection-Brompheniramine and codeine
- Tacrolimus Injection-Brompheniramine and phenylephrine
- Tacrolimus Injection-Brompheniramine and Phenylephrine Chewable Tablets
- Tacrolimus Injection-Brompheniramine and Phenylephrine Liquid
- Tacrolimus Injection-Brompheniramine and Phenylephrine Suspension